MICROBOT MEDICAL INC. - COMMON STOCK

Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial

08 7 2024 08:20:00 提供 Nasdaq GlobeNewswire

Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial

03 7 2024 08:20:00 提供 Nasdaq GlobeNewswire

Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial

20 6 2024 08:25:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial

17 6 2024 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

04 6 2024 16:20:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

03 6 2024 12:11:00 提供 Nasdaq GlobeNewswire

Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial

03 6 2024 08:20:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™

29 4 2024 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Shares Status Following Recent Geopolitical Events

15 4 2024 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

05 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters

30 1 2024 07:20:00 提供 Nasdaq GlobeNewswire

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

18 1 2024 07:20:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

29 12 2023 08:00:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met

28 12 2023 07:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic

14 12 2023 08:15:00 提供 Nasdaq GlobeNewswire

Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study

07 12 2023 08:00:00 提供 Nasdaq GlobeNewswire

Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities

21 11 2023 09:12:03 提供 Nasdaq GlobeNewswire

Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process

13 11 2023 08:30:00 提供 Nasdaq GlobeNewswire

Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office

08 11 2023 09:10:00 提供 Nasdaq GlobeNewswire

Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study

31 10 2023 08:25:00 提供 Nasdaq GlobeNewswire